End-of-day quote
Shenzhen S.E.
06:00:00 2024-05-13 pm EDT
|
5-day change
|
1st Jan Change
|
18.06
CNY
|
-2.59%
|
|
-1.79%
|
-22.42%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,897
|
3,379
|
2,462
|
2,400
|
3,864
|
2,794
|
Enterprise Value (EV)
1 |
2,896
|
3,353
|
2,519
|
2,465
|
3,947
|
3,018
|
P/E ratio
|
34.8
x
|
34.7
x
|
44.6
x
|
8.4
x
|
119
x
|
76.9
x
|
Yield
|
0.83%
|
0.89%
|
0.61%
|
1.25%
|
-
|
0.21%
|
Capitalization / Revenue
|
4.07
x
|
3.66
x
|
3.49
x
|
4.15
x
|
7.34
x
|
5.39
x
|
EV / Revenue
|
4.07
x
|
3.63
x
|
3.57
x
|
4.26
x
|
7.5
x
|
5.83
x
|
EV / EBITDA
|
25.3
x
|
23.2
x
|
26
x
|
37.2
x
|
47.8
x
|
31.1
x
|
EV / FCF
|
-131
x
|
83.7
x
|
-35.7
x
|
115
x
|
-16.9
x
|
-16.9
x
|
FCF Yield
|
-0.77%
|
1.2%
|
-2.8%
|
0.87%
|
-5.9%
|
-5.91%
|
Price to Book
|
4.99
x
|
5.17
x
|
3.62
x
|
2.53
x
|
4.06
x
|
2.83
x
|
Nbr of stocks (in thousands)
|
120,000
|
120,000
|
120,000
|
120,000
|
120,000
|
120,000
|
Reference price
2 |
24.14
|
28.16
|
20.52
|
20.00
|
32.20
|
23.28
|
Announcement Date
|
4/1/19
|
4/8/20
|
4/7/21
|
4/21/22
|
4/24/23
|
4/24/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
711.9
|
924.5
|
706.3
|
578.3
|
526.5
|
517.8
|
EBITDA
1 |
114.3
|
144.8
|
96.99
|
66.26
|
82.56
|
96.97
|
EBIT
1 |
97.59
|
117.2
|
65.59
|
29.41
|
34.63
|
43.52
|
Operating Margin
|
13.71%
|
12.67%
|
9.29%
|
5.09%
|
6.58%
|
8.4%
|
Earnings before Tax (EBT)
1 |
95.97
|
114.2
|
61.35
|
330.4
|
28.78
|
37.69
|
Net income
1 |
83.22
|
97.26
|
55.23
|
285.9
|
32.45
|
36.32
|
Net margin
|
11.69%
|
10.52%
|
7.82%
|
49.43%
|
6.16%
|
7.01%
|
EPS
2 |
0.6935
|
0.8105
|
0.4603
|
2.382
|
0.2704
|
0.3026
|
Free Cash Flow
1 |
-22.16
|
40.09
|
-70.62
|
21.51
|
-232.9
|
-178.4
|
FCF margin
|
-3.11%
|
4.34%
|
-10%
|
3.72%
|
-44.24%
|
-34.46%
|
FCF Conversion (EBITDA)
|
-
|
27.69%
|
-
|
32.46%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
41.22%
|
-
|
7.52%
|
-
|
-
|
Dividend per Share
2 |
0.2000
|
0.2500
|
0.1250
|
0.2500
|
-
|
0.0500
|
Announcement Date
|
4/1/19
|
4/8/20
|
4/7/21
|
4/21/22
|
4/24/23
|
4/24/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
57
|
64.7
|
83.1
|
224
|
Net Cash position
1 |
1.27
|
25.9
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
0.5873
x
|
0.9762
x
|
1.006
x
|
2.312
x
|
Free Cash Flow
1 |
-22.2
|
40.1
|
-70.6
|
21.5
|
-233
|
-178
|
ROE (net income / shareholders' equity)
|
15.2%
|
15.7%
|
8.18%
|
35%
|
3.38%
|
3.75%
|
ROA (Net income/ Total Assets)
|
8.55%
|
8.8%
|
4.62%
|
1.66%
|
1.67%
|
2.01%
|
Assets
1 |
973.2
|
1,105
|
1,196
|
17,174
|
1,946
|
1,804
|
Book Value Per Share
2 |
4.840
|
5.450
|
5.660
|
7.920
|
7.920
|
8.230
|
Cash Flow per Share
2 |
0.8400
|
1.250
|
0.8600
|
0.9600
|
0.7900
|
0.3900
|
Capex
1 |
76.7
|
43.4
|
120
|
94.4
|
219
|
197
|
Capex / Sales
|
10.77%
|
4.69%
|
17%
|
16.33%
|
41.59%
|
38.09%
|
Announcement Date
|
4/1/19
|
4/8/20
|
4/7/21
|
4/21/22
|
4/24/23
|
4/24/24
|
|
1st Jan change
|
Capi.
|
---|
| -22.42% | 308M | | +31.06% | 682B | | +30.35% | 586B | | -3.42% | 364B | | +18.02% | 327B | | +4.27% | 285B | | +15.53% | 240B | | +10.16% | 209B | | -8.14% | 203B | | +8.12% | 165B |
Other Pharmaceuticals
|